
Decoding the PAAG Advantage: How Age, Lower KL Grade, and Non-Diabetic Status Shape Knee OA Outcomes
Polyacrylamide hydrogel (PAAG) injections are emerging as a minimally invasive treatment for knee osteoarthritis (OA), offering pain relief and improved joint function. Recent studies show PAAG is most effective in older adults without diabetes and those with less advanced OA (lower Kellgren–Lawrence grade). Patient-reported outcomes—including the Oxford Knee Score and Visual Analogue Scale—demonstrate clinically meaningful improvements that can last up to two years. Customizing PAAG therapy based on age, OA severity, and diabetes status helps ensure the best results, supporting a personalized approach to care. Learn how these factors influence PAAG success and the future of tailored knee OA treatments.




